Loading clinical trials...
Loading clinical trials...
A Dose Exploration Study of Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Newly Diagnosed or Recurrent Brain/Leptomeningeal Metastasis (ARTISTRY)
Conditions
Interventions
almonertinib
LM-first line treatment
+1 more
Locations
1
China
Henan Cancer Hospital
Zhengzhou, Henan, China
Start Date
March 20, 2021
Primary Completion Date
February 20, 2023
Completion Date
February 20, 2024
Last Updated
August 31, 2021
NCT05692635
NCT07486219
NCT06305754
NCT05098132
NCT06731413
NCT04585750
Lead Sponsor
Henan Cancer Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions